NEW YORK (GenomeWeb News) – Agilent Technologies announced today that it will split into two publicly-traded companies — one focused on its life science and diagnostics business and the other on its electronic measurement business.

The life sciences and diagnostics business, which also includes applied markets, has annual revenues of around $3.9 billion. It will retain the Agilent name, and current Agilent CEO William Sullivan will retain the same role and also serve as president of the company. CFO Didier Hirsch also will continue as CFO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.